Evie Ring (Movano Health)

Overview

The Evie Ring is Movano Health’s first product — a smart ring designed exclusively for women’s health, focusing on menstrual cycle tracking, perimenopause symptoms, pregnancy support, mood, and general female-wellness biomarkers. Movano Health is a US public health-tech company (PLEASANTON, CA) with a clinical-research-led approach and a stated mission to bring medical-grade health tracking to women specifically.

In the 2026 smart-ring landscape, Evie Ring sits in a unique niche: it’s the only smart ring whose product design, app experience, and metric set are built first for women. The trade-off is competitive depth — Evie’s general fitness and workout features are weaker than gender-neutral competitors (Oura, Samsung, RingConn), and Movano Health has faced documented financial and supply-chain challenges that affect long-term confidence in the brand.

What We Measured

Note: This review is based on Movano Health’s published specifications, SEC filings (Movano Health is a publicly-traded company), and aggregated user reports. Hands-on instrument testing with Polar H10 + Kubios HRV (Bland–Altman analysis on 7-day continuous wear) is pending. Verdict will be updated upon completion.

Women’s-health-first design

The Evie Ring’s product distinction is fundamentally categorical, not just marketing. The app is built around:

• Menstrual cycle tracking and symptom logging with cycle-phase-aware insights
• Perimenopause feature support (irregular cycle handling, hot-flash logging, mood tracking)
• Pregnancy support with adapted metric interpretation during gestation
• Mood tracking with AI pattern recognition for cycle/mood correlations
• Fertility-window estimation (positioned as informational, not contraceptive)

This is meaningfully different from gender-neutral smart rings that tack on a “cycle tracking” feature. Evie’s underlying assumption is that female-typical hormonal patterns are the primary signal; everything else is secondary.

The open horseshoe form factor

Unlike Oura, RingConn, or Ultrahuman’s closed circular shells, the Evie Ring is a horseshoe / open-ended design that flexes with finger swelling. This is a real comfort advantage during menstrual or pregnancy-related fluid retention — closed rings can feel uncomfortably tight on swollen fingers. The trade-off is sensor coverage; the open design gives slightly less skin contact than a closed ring.

Sensor suite

Heart rate, HRV, SpO2, skin temperature, respiratory rate, sleep stages, sleep score, mood logging. The metric set covers the core consumer smart-ring inputs; what’s distinctive is the interpretation layer (cycle-phase-aware metric framing).

Build quality

Liquidmetal scratch-resistant body, ~4-day battery life, ~60-minute full charge. The 4-day battery is the shortest in our active smart-ring comparison set — meaningful daily charging compromise vs Oura (~6 days), RingConn (~10 days), Ultrahuman Ring Pro (~15 days).

Movano Health’s financial context

Movano Health is a publicly-traded company (NASDAQ: MOVE). The company has documented financial challenges including operating losses, supply-chain delays during product launch, and investor relations friction. This is editorially significant for buyers because long-term software support and warranty paths depend on the company’s continuing operations. We are not making a financial-distress prediction — but the risk profile is meaningfully different from a privately-held flagship like Oura or a corporate giant like Samsung.

3-Year Cost of Ownership

Component	Cost
Evie Ring	$269
Subscription	$0 (none)
3-year total — Evie	$269

Compare: Oura Ring 4 ($565), Apple Watch with cycle tracking ($399+), Natural Cycles app subscription (~$108/yr ~ $324 over 3 yrs).

For women specifically prioritizing cycle / women’s-health insights, the Evie Ring is competitive on price with the dedicated alternatives. For general-purpose fitness + sleep tracking, gender-neutral rings deliver more for the same money.

Regulatory Status

General Wellness Device. No FDA clearance for any specific medical claim. The cycle tracking and fertility-window features are positioned as informational wellness tools, not contraception or diagnostics.

This is consistent with most consumer smart rings. The notable comparison: Natural Cycles (the contraceptive app) holds an FDA De Novo clearance using temperature data; Oura Ring 4 integrates with Natural Cycles. Evie does not have a comparable FDA-cleared contraceptive integration.

When Evie Ring Makes Sense — And When It Doesn’t

Strong fit:

• You’re a woman specifically wanting cycle tracking, perimenopause support, or pregnancy-adapted metric interpretation.
• The open horseshoe form factor’s comfort advantage matters to you (swelling, fluid retention, varying finger size).
• You’re comfortable with a smaller brand’s longer-term support uncertainty.

Weaker fit:

• You want the longest battery — Ultrahuman Ring Pro (~15 days) or RingConn Gen 2 (~10 days) win clearly.
• You prioritize fitness / workout tracking — gender-neutral rings cover this more deeply.
• You want a brand with the strongest long-term operational continuity — Apple, Samsung, or Oura are more conservative picks.
• You want FDA-cleared contraceptive support — that’s Oura + Natural Cycles, not Evie.

Verdict: Conditional

The Evie Ring earns a conditional verdict for being the only smart ring designed first for women’s health, with a genuinely differentiated product design (horseshoe flex-fit, cycle-phase-aware interpretation, menstrual/perimenopause/pregnancy support) — balanced against the shorter battery, weaker fitness features, and the documented financial-context risk around Movano Health.

For women specifically prioritizing cycle / women’s-health features in a ring form factor, Evie is the most-aligned consumer product. For general-purpose smart-ring buyers, the gender-neutral flagships (Oura, RingConn, Samsung, Ultrahuman) deliver better all-around feature coverage at similar or lower cost.

We’ll re-evaluate after independent HRV-accuracy validation; if the underlying sensor data quality holds up, the conditional verdict applies primarily to the brand-continuity risk rather than the product itself.

Changelog

• 2026-05-05: Initial review published based on Movano Health specifications and aggregated user-report data. Hands-on Polar H10 + Kubios HRV validation pending.